MPRD Overview

Conceptual MindWorks, Inc. of San Antonio is a member of the Engility Corporation team that has been awarded a US Army’s $900M Medical Product Development (MPRD) Contract.

The Engility team is one of the awardees for the MPRD contract. The other contract awardees include Dynport Vaccine, Leidos, and Pharmaceutical Product Development.
The indefinite-delivery, indefinite-quantity contract covers the provision of professional and technical services supporting MPRD for the army and other Department of Defense entities, and has a five-year base performance period, as well as five, one-year options.

Engility president and CEO Tony Smeraglinolo said: “Engility appreciates the opportunity to provide unique technical support and innovative thought on this vital medical product research and development program, which ensures the servicemen and women who defend our country have the best medical supplies and medical assistance available.

“The MPRD contract is a very meaningful award and is projected to be a vehicle that is used throughout DoD.”

“The MPRD contract is a very meaningful award and is projected to be a vehicle that is used throughout DoD for medical product research and development and support.”

The MPRD program provides a mechanism for all aspects of medical product research and development and lifecycle support to maintain US troops.

Managed by the Army Medical Research and Materiel Command, the contract will streamline the process, in which military medical products move through the development process and progress through Food and Drug Administration clearance or approval before fielding the product or knowledge to the soldier.

Task Order Awarded September 2016

Conceptual MindWorks (CMI) and Engility Conduct

Vaccine Trials for the US Army Medical Research and Material Command

Engility leads a team that has been selected by the U.S. Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research to conduct clinical trials on two candidate chikungunya vaccines. Engility has proven experience working with DOD medical customers and FDA regulators to ensure processes that meet both acquisition and regulatory requirements.

Conceptual MindWorks, Inc. (CMI) will ensure that data collection and analysis are of the highest quality. CMI has experience supporting all Biomedical Advanced Research and Development Authority* (BARDA) clinical trials for influenza, emerging infectious disease and Chemical Biological Radiological and Nuclear medical countermeasures over the past 5 years.

The Engility team will apply commercial best practices that will ensure unique considerations for vaccine studies to better address potential risks; efficient site identification & qualification to ensure enrollment; and higher patient enrollment & retention.

*TeamCMI provides contracted staffing support to the Biomedical Advanced Research and Development Authority (BARDA), within the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response in Washington, DC. The mission of the BARDA is to develop and procure medical countermeasures (MCM) that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. Specifically, BARDA supports the advanced development and procurement of drugs, vaccines and other products that are considered priorities for national health security. For more information on BARDA please visit their website at: http://www.phe.gov/about/BARDA/Pages/default.aspx